Perspective Therapeutics (NYSEAMERICAN:CATX) Director Purchases 15,000 Shares of Company Stock

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX – Get Free Report) Director Frank Morich purchased 15,000 shares of the business’s stock in a transaction dated Monday, November 16th. The shares were purchased at an average price of $0.94 per share, for a total transaction of $14,100.00. Following the acquisition, the director directly owned 30,000 shares of the company’s stock, valued at $28,200. This trade represents a 100.00% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Frank Morich also recently made the following trade(s):

  • On Thursday, November 12th, Frank Morich purchased 15,000 shares of Perspective Therapeutics stock. The stock was purchased at an average price of $1.00 per share, with a total value of $15,000.00.

Perspective Therapeutics Stock Performance

Perspective Therapeutics stock opened at $0.92 on Tuesday. The company has a 50 day moving average price of $2.06 and a 200 day moving average price of $3.43. Perspective Therapeutics, Inc. has a 52 week low of $0.78 and a 52 week high of $6.16. The company has a quick ratio of 6.61, a current ratio of 5.18 and a debt-to-equity ratio of 0.01.

Perspective Therapeutics (NYSEAMERICAN:CATX – Get Free Report) last announced its earnings results on Monday, November 9th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.03). The firm had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.06 million. Perspective Therapeutics had a negative net margin of 55,866.82% and a negative return on equity of 42.25%. On average, equities analysts forecast that Perspective Therapeutics, Inc. will post -1.01 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. Provenance Wealth Advisors LLC bought a new stake in shares of Perspective Therapeutics in the 3rd quarter valued at approximately $44,000. Auctus Advisors LLC increased its position in Perspective Therapeutics by 83.6% during the third quarter. Auctus Advisors LLC now owns 37,359 shares of the company’s stock worth $103,000 after buying an additional 17,015 shares during the last quarter. Taylor & Morgan Wealth Management LLC increased its position in Perspective Therapeutics by 30.3% during the third quarter. Taylor & Morgan Wealth Management LLC now owns 86,000 shares of the company’s stock worth $236,000 after buying an additional 20,000 shares during the last quarter. Russell Investments Group Ltd. raised its holdings in Perspective Therapeutics by 53.1% during the third quarter. Russell Investments Group Ltd. now owns 61,012 shares of the company’s stock valued at $168,000 after buying an additional 21,150 shares in the last quarter. Finally, Quantinno Capital Management LP bought a new position in Perspective Therapeutics during the first quarter valued at about $273,000. 54.66% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Perspective Therapeutics

Investors following CATX have been watching these headlines:

  • Positive Sentiment: Several company insiders bought shares in open-market transactions on November 12. Purchases included 35,000 shares by Markus Puhlmann, 23,750 by director Lori Woods, and 24,898 by director Robert Williamson across two reported transactions. Director Frank Morich also bought 15,000 shares that day, then acquired another 15,000 shares on November 16 at an average of $0.94. The buying may signal insiders’ confidence, though it does not guarantee a recovery. Insider buying report Morich SEC filing
  • Neutral Sentiment: Analyst opinion remains broadly favorable, with nine Buy ratings and two Holds cited, but target cuts show increased caution: Wedbush lowered its target to $7 from $9, while Piper Sandler reduced its target to $14 from $16. Analyst ratings and estimates
  • Negative Sentiment: Perspective Therapeutics’ latest quarter fell short of forecasts: its loss was $0.27 per share versus the $0.24 expected, and revenue was $0.02 million versus $0.06 million expected. The stock is also far below its 50-day and 200-day moving averages and near its 12-month low, reflecting substantial recent weakness. CATX earnings information

Analysts Set New Price Targets

A number of brokerages have commented on CATX. Bank of America decreased their price objective on Perspective Therapeutics from $6.00 to $5.00 and set a “neutral” rating for the company in a research report on Friday, August 14th. BMO Capital Markets reissued an “outperform” rating on shares of Perspective Therapeutics in a research report on Friday, October 30th. Wedbush restated an “outperform” rating and set a $7.00 price target (down from $9.00) on shares of Perspective Therapeutics in a report on Tuesday, November 10th. BTIG Research reaffirmed a “buy” rating on shares of Perspective Therapeutics in a research report on Monday, October 26th. Finally, Royal Bank Of Canada lowered shares of Perspective Therapeutics from an “outperform” rating to a “sector perform” rating and dropped their price objective for the company from $14.00 to $4.00 in a research note on Monday, October 26th. Nine investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $10.10.

Get Our Latest Report on Perspective Therapeutics

Perspective Therapeutics Company Profile

(Get Free Report)

Perspective Therapeutics is a clinical-stage radiopharmaceutical company developing targeted alpha-particle therapies for cancer. Its approach combines radioactive lead-212 with molecules designed to bind to specific targets on tumor cells, with the goal of delivering radiation directly to tumors while limiting exposure to surrounding tissue. The company’s investigational pipeline includes therapies aimed at cancers such as neuroendocrine tumors and metastatic melanoma. Its programs include compounds designed to target somatostatin receptors and melanocortin 1 receptors.

Featured Articles

Insider Buying and Selling by Quarter for Perspective Therapeutics (NYSEAMERICAN:CATX)

Receive News & Ratings for Perspective Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perspective Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.